NVAX [NASD]
Novavax, Inc.
Index- P/E- EPS (ttm)-17.69 Insider Own0.20% Shs Outstand76.46M Perf Week-11.48%
Market Cap3.94B Forward P/E7.61 EPS next Y6.06 Insider Trans-25.08% Shs Float75.90M Perf Month-2.72%
Income-1317.60M PEG- EPS next Q5.18 Inst Own43.80% Short Float18.83% Perf Quarter-42.30%
Sales1.40B P/S2.81 EPS this Y-222.50% Inst Trans0.73% Short Ratio3.07 Perf Half Y-77.02%
Book/sh0.85 P/B54.27 EPS next Y-73.56% ROA-49.10% Target Price158.67 Perf Year-69.43%
Cash/sh- P/C- EPS next 5Y0.00% ROE-572.50% 52W Range41.33 - 277.80 Perf YTD-67.76%
Dividend- P/FCF- EPS past 5Y-2.50% ROI- 52W High-83.39% Beta1.43
Dividend %- Quick Ratio1.00 Sales past 5Y136.90% Gross Margin98.90% 52W Low11.61% ATR6.00
Employees1541 Current Ratio1.00 Sales Q/Q57.40% Oper. Margin-90.40% RSI (14)41.76 Volatility10.89% 13.39%
OptionableYes Debt/Eq6.75 EPS Q/Q184.00% Profit Margin-93.90% Rel Volume0.67 Prev Close46.54
ShortableYes LT Debt/Eq0.00 EarningsMay 09 AMC Payout- Avg Volume4.65M Price46.13
Recom2.10 SMA20-11.19% SMA50-24.16% SMA200-66.24% Volume3,131,586 Change-0.88%
May-20-22Initiated BofA Securities Underperform $35
Feb-23-22Reiterated B. Riley Securities Buy $315 → $265
Feb-22-22Resumed Jefferies Buy $198
Jan-21-22Initiated Cowen Outperform $150
May-12-21Downgrade JP Morgan Overweight → Neutral $285 → $161
Dec-14-20Initiated Jefferies Buy $200
Aug-06-20Reiterated H.C. Wainwright Buy $132 → $290
Aug-05-20Upgrade JP Morgan Neutral → Overweight $275
Aug-05-20Downgrade Ladenburg Thalmann Neutral → Sell $105
Jul-16-20Reiterated H.C. Wainwright Buy $101 → $132
Jul-08-20Downgrade Ladenburg Thalmann Buy → Neutral $50 → $105
Jun-29-20Reiterated H.C. Wainwright Buy $50 → $101
Jun-29-20Reiterated B. Riley FBR Buy $74 → $106
Jun-05-20Upgrade JP Morgan Underweight → Neutral $46
May-28-20Reiterated B. Riley FBR Buy $53 → $61
May-12-20Reiterated H.C. Wainwright Buy $33 → $50
Apr-30-20Reiterated H.C. Wainwright Buy $24 → $33
Nov-27-19Resumed B. Riley FBR Buy $12
Aug-14-19Reiterated H.C. Wainwright Buy $10 → $17
Feb-28-19Downgrade Piper Jaffray Overweight → Underweight $4.50 → $0.25
May-25-22 06:00AM  
May-24-22 12:01PM  
11:54AM  
05:21AM  
May-21-22 06:08AM  
May-20-22 12:08PM  
12:01PM  
10:43AM  
06:30AM  
May-19-22 06:40AM  
06:30AM  
05:06AM  
May-18-22 06:00AM  
May-13-22 02:08PM  
12:19PM  
11:00AM  
10:57AM  
10:00AM  
May-11-22 06:30AM  
May-10-22 02:47PM  
11:51AM  
10:59AM  
10:39AM  
10:22AM  
09:47AM  
08:29AM  
05:51AM  
05:06AM  
03:51AM  
May-09-22 05:35PM  
04:29PM  
04:28PM  
04:08PM  
04:02PM  
07:05AM  
May-07-22 05:06AM  
May-06-22 08:52AM  
05:50AM  
May-05-22 08:15AM  
May-04-22 08:55PM  
05:14PM  
04:02PM  
02:25PM  
10:11AM  
09:57AM  
May-03-22 07:32PM  
01:15PM  
07:49AM  
06:40AM  
May-02-22 04:02PM  
03:00PM  
11:56AM  
11:10AM  
09:48AM  
Apr-29-22 08:51PM  
05:45PM  
04:05PM  
11:38AM  
11:19AM  
11:07AM  
10:30AM  
09:42AM  
Apr-28-22 03:33PM  
Apr-27-22 05:01PM  
03:20PM  
10:53AM  
09:15AM  
09:00AM  
06:15AM  
06:00AM  
05:52AM  
Apr-25-22 01:24PM  
Apr-22-22 04:00PM  
07:50AM  
07:00AM  
Apr-21-22 11:58AM  
09:40AM  
09:24AM  
07:09AM  
06:30AM  
06:10AM  
Apr-20-22 05:27PM  
02:36PM  
12:43PM  
12:41PM  
12:40PM  
11:42AM  
Apr-19-22 11:26PM  
05:45PM  
07:15AM  
07:15AM  
04:13AM  
Apr-18-22 01:39PM  
11:22AM  
10:27AM  
10:13AM  
10:00AM  
09:35AM  
08:52AM  
07:05AM  
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
YOUNG JAMES FDirectorMar 31Sale73.5812,500919,76562,590Apr 04 05:14 PM
Herrmann John A IIIEVP, Chief Legal OfficerJan 03Option Exercise19.085,00095,4008,845Jan 05 05:22 PM
Herrmann John A IIIEVP, Chief Legal OfficerJan 03Sale140.915,000704,5343,845Jan 05 05:22 PM
YOUNG JAMES FDirectorDec 31Option Exercise25.603,75096,00078,840Jan 04 05:04 PM
YOUNG JAMES FDirectorDec 31Sale144.163,750540,60175,090Jan 04 05:04 PM
Herrmann John A IIIEVP, Chief Legal OfficerDec 20Option Exercise19.085,00095,4008,845Dec 22 05:03 PM
Herrmann John A IIIEVP, Chief Legal OfficerDec 20Sale230.005,0001,150,0003,845Dec 22 05:03 PM
Glenn Gregory MPresident, R&DDec 15Option Exercise34.821,68658,7147,349Dec 16 05:15 PM
Glenn Gregory MPresident, R&DDec 15Sale174.131,686293,5845,663Dec 16 05:15 PM
DOUGLAS RICHARDDirectorDec 13Option Exercise25.601,50038,40033,450Dec 15 05:22 PM
Glenn Gregory MPresident, R&DDec 07Option Exercise19.088,250157,41012,311Dec 09 05:20 PM
Glenn Gregory MPresident, R&DDec 07Sale170.148,2501,403,6314,061Dec 09 05:20 PM
Herrmann John A IIIEVP, Chief Legal OfficerDec 01Option Exercise19.085,00095,4007,760Dec 03 06:30 PM
Herrmann John A IIIEVP, Chief Legal OfficerDec 01Sale196.195,000980,9442,760Dec 03 06:30 PM
Glenn Gregory MPresident, R&DNov 30Option Exercise19.088,250157,41013,003Dec 02 04:13 PM
Glenn Gregory MPresident, R&DNov 30Sale203.208,9421,817,0004,061Dec 02 04:13 PM
Herrmann John A IIIEVP, Chief Legal OfficerNov 29Option Exercise19.085,00095,4007,760Dec 01 05:02 PM
Herrmann John A IIIEVP, Chief Legal OfficerNov 29Sale228.725,0001,143,6002,760Dec 01 05:02 PM
Glenn Gregory MPresident, R&DNov 26Option Exercise5.953,46020,5876,144Nov 30 05:06 PM
Glenn Gregory MPresident, R&DNov 26Sale218.072,083454,2474,061Nov 30 05:06 PM
Glenn Gregory MPresident, R&DNov 23Option Exercise19.088,250157,41012,311Nov 24 05:21 PM
Glenn Gregory MPresident, R&DNov 23Sale199.508,2501,645,9144,061Nov 24 05:21 PM
Glenn Gregory MPresident, R&DNov 16Option Exercise19.088,250157,41012,311Nov 17 05:25 PM
Glenn Gregory MPresident, R&DNov 16Sale169.488,2501,398,1804,061Nov 17 05:25 PM
Glenn Gregory MPresident, R&DNov 15Option Exercise37.901,18344,8325,244Nov 17 05:25 PM
Glenn Gregory MPresident, R&DNov 15Sale172.021,183203,4964,061Nov 17 05:25 PM
Glenn Gregory MPresident, R&DNov 09Option Exercise19.088,250157,41012,311Nov 12 05:02 PM
Glenn Gregory MPresident, R&DNov 09Sale167.538,2501,382,1604,061Nov 12 05:02 PM
Herrmann John A IIIEVP, Chief Legal OfficerNov 03Option Exercise19.085,00095,4007,760Nov 05 05:02 PM
Herrmann John A IIIEVP, Chief Legal OfficerNov 03Sale200.005,0001,000,0002,760Nov 05 05:02 PM
Glenn Gregory MPresident, R&DNov 02Option Exercise19.088,250157,41012,311Nov 04 05:22 PM
Glenn Gregory MPresident, R&DNov 02Sale183.828,2501,516,5524,061Nov 04 05:22 PM
Herrmann John A IIIEVP, Chief Legal OfficerNov 01Option Exercise19.085,00095,4007,760Nov 03 04:49 PM
Herrmann John A IIIEVP, Chief Legal OfficerNov 01Sale163.085,000815,4222,760Nov 03 04:49 PM
Glenn Gregory MPresident, R&DOct 29Sale148.34680100,8714,061Nov 02 07:02 PM
Glenn Gregory MPresident, R&DOct 26Option Exercise15.2011,712178,00914,395Oct 28 05:09 PM
Glenn Gregory MPresident, R&DOct 26Sale132.7310,3341,371,6674,061Oct 28 05:09 PM
Glenn Gregory MPresident, R&DOct 19Option Exercise19.088,250157,41012,311Oct 21 05:08 PM
Glenn Gregory MPresident, R&DOct 19Sale165.148,2501,362,4274,061Oct 21 05:08 PM
Glenn Gregory MPresident, R&DOct 15Option Exercise37.901,18344,8325,244Oct 19 05:04 PM
Glenn Gregory MPresident, R&DOct 15Sale170.001,183201,1104,061Oct 19 05:04 PM
Glenn Gregory MPresident, R&DOct 12Option Exercise19.088,250157,41012,311Oct 14 05:16 PM
Glenn Gregory MPresident, R&DOct 12Sale163.188,2501,346,2184,061Oct 14 05:16 PM
Glenn Gregory MPresident, R&DOct 05Option Exercise19.088,250157,41012,311Oct 07 05:18 PM
Glenn Gregory MPresident, R&DOct 05Sale174.418,2501,438,8954,061Oct 07 05:18 PM
Erck Stanley CPresident and CEOOct 04Option Exercise27.4542,8291,175,58366,708Oct 05 05:05 PM
Erck Stanley CPresident and CEOOct 04Sale176.1542,8297,544,19523,879Oct 05 05:05 PM
Herrmann John A IIIEVP, Chief Legal OfficerOct 01Option Exercise19.085,00095,4007,760Oct 05 05:02 PM
Erck Stanley CPresident and CEOOct 01Option Exercise27.1749,0001,331,40072,879Oct 05 05:04 PM
Erck Stanley CPresident and CEOOct 01Sale175.1049,0008,580,06423,879Oct 05 05:04 PM
Herrmann John A IIIEVP, Chief Legal OfficerOct 01Sale174.895,000874,4522,760Oct 05 05:02 PM
Glenn Gregory MPresident, R&DSep 30Sale207.25693143,6224,061Oct 01 05:58 PM
Trizzino JohnEVP, CCO and CBOSep 28Option Exercise19.087,501143,11910,047Sep 29 05:06 PM
Trizzino JohnEVP, CCO and CBOSep 28Sale209.927,5011,574,6372,546Sep 29 05:06 PM
Glenn Gregory MPresident, R&DSep 27Option Exercise5.953,46020,5876,144Sep 29 05:08 PM
Trizzino JohnEVP, CCO and CBOSep 27Option Exercise19.087,501143,11910,047Sep 29 05:04 PM
Trizzino JohnEVP, CCO and CBOSep 27Sale234.617,5011,759,8332,546Sep 29 05:04 PM
Glenn Gregory MPresident, R&DSep 27Sale234.432,083488,3154,061Sep 29 05:08 PM
MOTT DAVID MDirectorSep 23Sale252.9024,9616,312,61640,000Sep 24 05:10 PM
Trizzino JohnEVP, CCO and CBOSep 21Option Exercise19.087,500143,1008,218Sep 22 05:05 PM
Trizzino JohnEVP, CCO and CBOSep 21Sale227.377,5001,705,265718Sep 22 05:05 PM
Trizzino JohnEVP, CCO and CBOSep 20Option Exercise19.087,500143,1008,218Sep 22 05:05 PM
Trizzino JohnEVP, CCO and CBOSep 20Sale227.577,5001,706,748718Sep 22 05:05 PM
Glenn Gregory MPresident, R&DSep 15Option Exercise37.901,18344,8325,244Sep 17 05:08 PM
Herrmann John A IIIEVP, Chief Legal OfficerSep 15Option Exercise19.085,00095,4005,706Sep 17 05:11 PM
Herrmann John A IIIEVP, Chief Legal OfficerSep 15Sale229.445,0001,147,193706Sep 17 05:11 PM
Glenn Gregory MPresident, R&DSep 15Sale229.341,183271,3044,061Sep 17 05:08 PM
Trizzino JohnEVP, CCO and CBOSep 14Option Exercise19.087,499143,0818,217Sep 15 05:03 PM
Trizzino JohnEVP, CCO and CBOSep 14Sale236.617,4991,774,360718Sep 15 05:03 PM
Trizzino JohnEVP, CCO and CBOSep 13Option Exercise19.087,499143,0818,217Sep 15 05:03 PM
Trizzino JohnEVP, CCO and CBOSep 13Sale235.297,4991,764,433718Sep 15 05:03 PM
Herrmann John A IIIEVP, Chief Legal OfficerSep 01Option Exercise19.085,00095,4005,706Sep 03 05:10 PM
Herrmann John A IIIEVP, Chief Legal OfficerSep 01Sale247.975,0001,239,867706Sep 03 05:10 PM
Glenn Gregory MPresident, R&DAug 31Sale239.871,386332,4634,061Sep 01 05:23 PM
Glenn Gregory MPresident, R&DAug 26Option Exercise5.956,92141,1808,228Aug 30 06:16 PM
Glenn Gregory MPresident, R&DAug 26Sale233.924,167974,7404,061Aug 30 06:16 PM
Glenn Gregory MPresident, R&DAug 16Option Exercise40.641,86675,8265,927Aug 18 05:26 PM
Glenn Gregory MPresident, R&DAug 16Sale233.521,866435,7504,061Aug 18 05:26 PM
Herrmann John A IIIEVP, Chief Legal OfficerJul 26Option Exercise14.832,89642,9603,602Jul 28 05:00 PM
Herrmann John A IIIEVP, Chief Legal OfficerJul 26Sale197.742,896572,648706Jul 28 05:00 PM
Glenn Gregory MPresident, R&DJul 20Sale215.432,409518,9822,811Jul 22 05:20 PM
Glenn Gregory MPresident, R&DJul 15Option Exercise13.0810,477137,0068,465Jul 19 07:52 PM
Glenn Gregory MPresident, R&DJul 15Sale179.455,6541,014,5972,811Jul 19 07:52 PM
Erck Stanley CPresident and CEOJul 02Option Exercise80.6652,5594,239,51173,054Jul 06 05:03 PM
Erck Stanley CPresident and CEOJul 02Sale215.8952,55911,347,06620,495Jul 06 05:03 PM
Erck Stanley CPresident and CEOJul 01Option Exercise61.5952,6203,240,96573,115Jul 06 05:03 PM
Erck Stanley CPresident and CEOJul 01Sale212.8852,62011,201,51320,495Jul 06 05:03 PM
Glenn Gregory MPresident, R&DJun 17Sale183.282,411441,8872,811Jun 17 06:17 PM
Glenn Gregory MPresident, R&DJun 15Option Exercise13.1610,535138,6858,527Jun 17 06:17 PM
Glenn Gregory MPresident, R&DJun 15Sale191.425,7161,094,1302,811Jun 17 06:17 PM
EVANS GARY CDirectorJun 01Sale146.5062591,5620Jun 03 05:34 PM
Herrmann John A IIIEVP, Chief Legal OfficerMay 28Option Exercise14.832,89542,9323,170Jun 02 04:59 PM
Herrmann John A IIIEVP, Chief Legal OfficerMay 28Sale149.142,895431,748275Jun 02 04:59 PM